Table 2 |
|||
|
VDR-FokI polymorphism in study subjects analyzed with respect to GAD65 antibody status |
|||
|
GAD65-positive |
GAD65-negative |
Controls |
|
|
T1DM |
T1DM |
||
|
n = 48 |
n = 30 |
n = 250 |
|
|
|
|||
|
Genotype frequenciesa |
|||
|
FF |
26 (54%) |
10(33%) |
82 (33%) |
|
Ff |
19 (40%) |
18(60%) |
138 (55%) |
|
ff |
3(6%) |
2(7%) |
30 (12%) |
|
Allele frequenciesb |
|||
|
F |
71 (74%) |
38(63%) |
302(60%) |
|
f |
25 (26%) |
22(37%) |
198(40%) |
|
Phenotype frequenciesc |
|||
|
F positive |
45 (94%) |
28 (94%) |
220(88%) |
|
f positive |
22 (46%) |
20 (67%) |
168(67%) |
|
|
|||
|
Values shown are the number of subjects with the percentage in parentheses. aΧ2 test of heterogeneity between GAD65-positive T1DM patients and control subjects. Χ2 = 8.14, 2 degrees of freedom; P = 0.017. bΧ2 test of heterogeneity between GAD65-positive T1DM patients and control subjects. Χ2 = 6.32, 1 degree of freedom; P = 0.012. cRelative risk ratio for F phenotype (GAD65-positive T1DM) = 2.0. |
|||
|
Ban et al. BMC Medical Genetics 2001 2:7 doi:10.1186/1471-2350-2-7 |
|||
